UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/657,353	09/08/2003	Michael R.S. Hill	P-9097 (2620/17-2)	1650	
JEFFREY J. HO	7590 04/10/2007 CHENSHELL	EXAMINER			
710 MEDTRONIC PARKWAW			OROPEZA, FRANCES P		
MINNEAPOLI	S, MO 55432		ART UNIT	PAPER NUMBER	
			3766	3766	
		NAME DATE		V MODE	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
3 MOI	NTHS	04/10/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

•		Application No.	Applicant(s)	<u> </u>			
Office Action Summary		10/657,353	HILL ET AL.				
		Examiner	Art Unit				
	·	Frances P. Oropeza	3766				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence add	ress			
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be time fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. ely filed the mailing date of this con O (35 U.S.C. § 133).	•			
Status		•					
1)	Responsive to communication(s) filed on <u>1/25/6</u>	07 (Response).					
, —	This action is FINAL . 2b) ☐ This	•					
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
,	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
Dispositi	on of Claims						
4) 🖂	4) Claim(s) 1-10 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
•	6) Claim(s) 1-10 is/are rejected.						
•	Claim(s) is/are objected to.			·			
· 8)	Claim(s) are subject to restriction and/or	election requirement.					
Applicati	on Papers	•					
9) 🗌 .	The specification is objected to by the Examiner	Γ .					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	ected to. See 37 CFF	R 1.121(d).			
11) 🗌 .	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTC	D-152.			
Priority u	ınder 35 U.S.C. § 119						
	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	-(d) or (f)				
, —	☐ All b)☐ Some * c)☐ None of:	priority under 55 C.C.C. 3 116(a)	(d) 01 (l).				
۵/۱	1. Certified copies of the priority documents	s have been received.					
	2. Certified copies of the priority documents		on No				
	3. Copies of the certified copies of the prior		•	stage			
	application from the International Bureau	(PCT Rule 17.2(a)).					
* S	see the attached detailed Office action for a list of	of the certified copies not receive	d.				
	·						
Attachment	r(s)						
	e of References Cited (PTO-892)	4) Interview Summary	`				
	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail Da 5) Notice of Informal Pa					
•	No(s)/Mail Date <u>1/25/07</u> .	6) Other:					

Page 2

Application/Control Number: 10/657,353

Art Unit: 3766

DETAILED ACTION

Response

1. The Applicant at least amended independent claim 1 in the response filed 1/25/07, hence the rejection of record is withdrawn and a new rejection established in the subsequent paragraph.

Claim Rejections - 35 USC § 112

- 2. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- Claims 1-10 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. In claim 1, the Examiner is unable to find "directly" in the instant specification. New matter may not be added at this point in the examination process. Appropriate correction is required.

Claim Rejections - 35 USC § 102

4. Claims 1-4 and 6-10 are rejected under 35 U.S.C. 102(e) as being anticipated by Duhaylongsod (US 6414018). Duhaylongsod teaches a method of performing a medical

Application/Control Number: 10/657,353

Art Unit: 3766

procedure comprising stimulating a vagal nerve to adjust to a first condition (asystole), delivering a first vasoactive substance (a beta-blocker, a cholinergic agent, nitroglycerine), performing a procedure (a coronary procedure/ coronary bypass procedure), and delivering a second vasoactive substance (a beta-blocker, a cholinergic agent, nitroglycerine, atropine) OR stimulating the heart to attain a second condition (using an electrical pacing system), and delivering a second vasoactive substance (a beta-blocker, a cholinergic agent, nitroglycerine, atropine) (abstract; col. 5 @ 27-46; col. 6 @ 44-50; col. 7 @ 24-34; col. 11 @ 13-35; col. 12 @ 18-24; col. 13 @ 32-39; col. 16 @ 38-43; col. 18 @ 10-12).

As to claim 1 and the delivery of the substances to a targeted vessel, Duhaylongsod teaches delivery of pharmacological substances to targeted vessels (col. 6 @ 25-30; col. 18 @ 22-27).

Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Duhaylongsod (US 6414018) in view of Maroko (US 5153178). As discussed in paragraph 6 of this action, Duhaylongsod discloses the claimed invention except for the second substance being a vasoconstrictor, specifically epinephrine.

Marok teaches improving circulation performance using the vasoconstrictor epinephrine for the purpose of increasing the contractibility of the mammalian heart. It would have been obvious to one having ordinary skill in the art at the time of the invention to have used the vasoconstrictor epinephrine in the Duhaylongsod system in order to provide an alternate means to controls the heart using a pharmacological agent that improves cardiac performance (abstract; col. 1 @ 19-30; col. 23 @ 13-29; col. 34 @ 33-41).

Application/Control Number: 10/657,353

Art Unit: 3766

Specification

6. The amendment filed 1/25/07 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: In claim 1, the word "directly".

The Applicant is required to cancel the new matter in the reply to this Office Action.

Statutory Basis

7. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Conclusion

The Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Application/Control Number: 10/657,353

Art Unit: 3766

Page 5

however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Fran Oropeza whose telephone number is (571) 272-4953. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Carl H. Layno can be reached on (571) 272-4949. The fax phone numbers for the organization where this application or proceeding is assigned is (571) 273-8300 for regular communication and for After Final communications.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Carl H. Lagra CARL LAYNO PRIMARY EXAMINER

ACTING SPE, AU3766

Frances P. Oropeza Patent Examiner Art Unit 3766